Answers are grounded in this paper and cite their sources.
Background: Clinical data on existing therapies for SMARCA4-mutated tumors are scarce, hindering the development of new agents targeting these mutations.
No takes yet. Share an insight, caveat, or question.
Murata et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: